Modèle BioRender

Atopic Dermatitis: Therapeutic Molecules Targeting Pruritus

Créé par

Gaia Lugano

•

BioRender Team

Utiliser ce modèle – Gratuit

Aucune carte de crédit requise pour l'inscription.

Ce modèle est entièrement modifiable dans BioRender

Remplacez le texte, les formes et les icônes
Changez les couleurs et réorganisez chaque icône, ligne et étiquette
Exportez ou partagez pour tout type d'utilisation

Rejoignez plus de 4 millions de scientifiques qui créent déjà des figures prêtes pour la publication

Description: This template shows therapeutic molecules targeting pruritus in atopic dermatitis by acting on NK1R, IL-31R, and P2X3 receptors on sensory nerve endings in the skin. Serlopitant and tradipitant block NK1R, nemolizumab and vixarelimab block IL-31R, and BLU-5937 blocks P2X3 to reduce itch signaling from the affected epidermis.

Les icônes et modèles BioRender respectent les normes des revues, des subventions et du droit d'auteur. Pour les figures générées par IA, les politiques varient. En savoir plus

Ce n'est pas tout à fait le bon modèle ? Découvrez-en plus.

Recherchez parmi des milliers de modèles dans plus de 30 domaines des sciences de la vie.

Sujets populaires :

Cell

Cancer

Administration de médicaments

Mécanisme d'action

Voie métabolique

Essayez un synonyme ou inscrivez-vous pour suggérer un modèle depuis l'application.

Nouveaux modèles

Kidney Reabsorption and Secretion

Alzheimer's Brain (Disintegrating Microtubule)

Favipiravir: Potential Repurposed Drug Candidate for COVID-19

Schematic of Spike-Receptor Binding Mechanism of SARS-CoV-2

Arabidopsis Rosette Mutants

Amplification of DNA Fragments Inserted into a Plasmid

Virtual Background - Night City

Periodic Table 2 Thank You E-Card

FAQ sur les modèles BioRender

What does the Atopic Dermatitis: Therapeutic Molecules Targeting Pruritus template show?

This template shows therapeutic molecules targeting pruritus in atopic dermatitis by acting on NK1R, IL-31R, and P2X3 receptors on sensory nerve endings in the skin. Serlopitant and tradipitant block NK1R, nemolizumab and vixarelimab block IL-31R, and BLU-5937 blocks P2X3 to reduce itch signaling from the affected epidermis.

Is the Atopic Dermatitis: Therapeutic Molecules Targeting Pruritus template free to use?

Yes, you can customize this template with a free BioRender account (no credit card required). Paid plans unlock additional export formats, higher-resolution downloads, and publication permissions.

Can I edit or customize this template?

Yes, every element is fully editable. Icons, labels, colors, arrows, shapes and layout can all be changed to match your preferences or needs using BioRender's drag-and-drop editor. You can add or remove elements to fully customize your use case.

Is this template accepted for use in journals, theses, or grant applications?

Yes, BioRender icons and templates meet journal, grant, and copyright standards for publication, and many researchers cite BioRender directly in their figure legends.

How do I cite BioRender if I use this template?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

What is Atopic Dermatitis: Therapeutic Molecules Targeting Pruritus used for / who typically uses this template?

Researchers and scientists use this template for publications, funding proposals, grant applications, presentations, posters, and more.